About the Authors
- Beat Nyfeler
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Yan Chen
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Xiaoyan Li
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Maria Pinzon-Ortiz
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Zuncai Wang
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Anupama Reddy
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Elina Pradhan
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Rita Das
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Joseph Lehár
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Robert Schlegel
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Peter M. Finan
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Z. Alexander Cao
-
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Leon O. Murphy
-
Affiliation Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
- Alan Huang
-
* E-mail: alan.huang@novartis.com
Affiliation Oncology Translational Medicine, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, United States of America
Competing Interests
The authors have read the journal's policy and have the following conflicts. Beat Nyfeler, Yan Chen, Xiaoyan Li, Maria Pinzon-Ortiz, Anupama Reddy, Joseph Lehar, Robert Schlegel, Peter M. Finan, Z. Alex Cao, Leon O. Murphy and Alan Huang are employees and/or share holders of Novartis Pharma AG. BEZ235 and RAD001 are either development or marketed products of Novartis Pharma AG. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: BN RS PMF ZAC LOM AH. Performed the experiments: YC XL MP-O ZW EP RD. Analyzed the data: BN AR JL ZAC AH. Wrote the paper: BN AR ZAC AH.